Brokerages Set Oscar Health, Inc. (NYSE:OSCR) PT at $12.21

Key Points

• Oscar Health, Inc. has received a consensus rating of "Strong Sell" from nine brokerages, with five analysts recommending a sell and four a hold.
• The average 12-month price target for Oscar Health's stock is $12.21, reflecting a downturn from previous targets set by various analysts.
• In its latest earnings report, Oscar Health surpassed earnings expectations with $0.92 EPS, contributing to a revenue increase of 42.2% year-over-year, totaling $3 billion.

Shares of Oscar Health, Inc. (NYSE:OSCR - Get Free Report) have received an average rating of "Strong Sell" from the nine research firms that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $12.21.

Several research analysts recently issued reports on the stock. Raymond James Financial lowered shares of Oscar Health from an "outperform" rating to a "market perform" rating in a research report on Tuesday, June 24th. Wall Street Zen cut Oscar Health from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. UBS Group reissued a "sell" rating and issued a $11.00 target price (down from $15.00) on shares of Oscar Health in a report on Tuesday, July 15th. Barclays lowered their price target on Oscar Health from $17.00 to $11.00 and set an "underweight" rating on the stock in a research report on Wednesday, July 23rd. Finally, Wells Fargo & Company cut Oscar Health from an "equal weight" rating to an "underweight" rating and lowered their price target for the company from $16.00 to $10.00 in a research report on Friday, July 11th.

Oscar Health Stock Performance

OSCR stock traded down $0.47 during mid-day trading on Thursday, reaching $13.58. 20,300,812 shares of the stock traded hands, compared to its average volume of 12,952,738. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average of $15.87 and a two-hundred day moving average of $14.91. The firm has a market capitalization of $3.46 billion, a PE ratio of 48.50 and a beta of 1.90. Oscar Health has a 52 week low of $11.20 and a 52 week high of $23.79.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.83 by $0.09. The company had revenue of $3 billion for the quarter, compared to the consensus estimate of $2.87 billion. Oscar Health had a return on equity of 10.59% and a net margin of 1.22%. The company's revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 EPS. As a group, equities analysts predict that Oscar Health will post 0.69 EPS for the current fiscal year.

Insider Buying and Selling at Oscar Health

In other news, Director Elbert O. Jr. Robinson sold 25,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $16.43, for a total transaction of $410,750.00. Following the sale, the director directly owned 64,512 shares of the company's stock, valued at $1,059,932.16. This represents a 27.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 24.39% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Oscar Health by 3.7% during the first quarter. Vanguard Group Inc. now owns 19,698,442 shares of the company's stock worth $258,247,000 after acquiring an additional 700,469 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in Oscar Health by 50.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 11,835,000 shares of the company's stock worth $159,062,000 after purchasing an additional 3,983,325 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Oscar Health by 4.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 11,826,245 shares of the company's stock worth $155,043,000 after purchasing an additional 467,301 shares during the period. JPMorgan Chase & Co. raised its holdings in Oscar Health by 348.7% during the 4th quarter. JPMorgan Chase & Co. now owns 10,360,529 shares of the company's stock worth $139,246,000 after purchasing an additional 8,051,379 shares during the last quarter. Finally, Thrive Capital Management LLC lifted its position in Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock valued at $85,258,000 after purchasing an additional 1,588,395 shares during the period. Institutional investors and hedge funds own 75.70% of the company's stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.